Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Tetravalent CYD Dengue Vaccine , 5555 formulation
Tetravalent CYD Dengue Vaccine, 5555 formulation · 1 trial · 3 indications
Percentage of participants with antibody titers \>= 10 (1/dil) against each serotypes (1, 2, 3 and 4) of the dengue virus strains was assessed by dengue plaque reduction neutralization test (PRNT).
| Arm | Type | Description |
|---|---|---|
| CYD Dengue Vaccine 5555 Formulation | EXPERIMENTAL | Participants received 3 doses of CYD dengue vaccine (5555 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months. |
| CYD Dengue Vaccine 5553 Formulation | EXPERIMENTAL | Participants received 3 doses of CYD dengue vaccine (5553 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months. |
| CYD Dengue Vaccine 4444 Formulation | EXPERIMENTAL | Participants received 3 doses of CYD dengue vaccine (4444 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months. |
| Name | Type | Description |
|---|---|---|
| Tetravalent CYD Dengue Vaccine , 5555 formulation | BIOLOGICAL | A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively. |
| Tetravalent CYD Dengue Vaccine , 5553 formulation | BIOLOGICAL | A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively |
| Tetravalent CYD Dengue Vaccine, 4444 formulation | BIOLOGICAL | A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively |
Inclusion Criteria: * Healthy, as determined by medical history, clinical examination, and biological safety parameters. * Aged 18 to 45 years on the day of inclusion. * Provision of informed consent signed by the participant or another legally acceptable representative. * For a woman of child-bear...
Tetravalent CYD Dengue Vaccine, 5555 formulation is an investigational vaccine developed by Sanofi for the prevention of dengue fever. It is a tetravalent candidate, meaning it is designed to cover four dengue virus serotypes, and it was studied in healthy adults aged 18 to 45 years in the United States.
Tetravalent CYD Dengue Vaccine, 5555 formulation is being developed for dengue fever, including dengue hemorrhagic fever and dengue virus infection. It is a preventive vaccine candidate rather than a treatment, and it has been evaluated in healthy adult volunteers in the United States.
Sanofi is the developer of Tetravalent CYD Dengue Vaccine, 5555 formulation. Sanofi trades on the New York Stock Exchange under the ticker SNY. The company sponsored the clinical program for this dengue vaccine candidate.
Tetravalent CYD Dengue Vaccine, 5555 formulation is in Phase 2 development. It is an investigational vaccine candidate and is not approved for use. The Phase 2 study evaluating this formulation has been completed.
Tetravalent CYD Dengue Vaccine, 5555 formulation was studied in one completed Phase 2 trial, NCT00617344, titled Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US. The randomized, double-blind, controlled trial enrolled 260 participants in the United States.
Tetravalent CYD Dengue Vaccine, 5555 formulation is also written as Tetravalent CYD Dengue Vaccine , 5555 formulation. The 5555 designation identifies this specific formulation of the tetravalent CYD dengue vaccine candidate developed by Sanofi, distinguishing it from other formulations tested in the same clinical program.